Welcome to our dedicated page for Tourmaline Bio SEC filings (Ticker: TRML), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a 300-page biotech filing packed with cytokine charts and trial acronyms is daunting. Tourmaline Bio’s disclosures around pacibekitug, cash runway, and FDA interactions are especially technical. If you have ever searched, "Tourmaline Bio SEC filings explained simply" or wondered how a single 8-K about interim data could move the stock, you are not alone.
Stock Titan turns that complexity into clarity. Our AI instantly extracts what matters from every Tourmaline Bio quarterly earnings report 10-Q filing, highlights safety signals buried in the 10-K, and delivers real-time alerts on Tourmaline Bio Form 4 insider transactions real-time. Need to track Tourmaline Bio insider trading Form 4 transactions before a read-out? Curious whether R&D spend rose quarter over quarter? Prefer a plain-English summary of an Tourmaline Bio 8-K material events explained? One click surfaces it all—along with AI-powered summaries, keyword search inside documents, and side-by-side comparisons of past filings.
Investors use these insights to monitor clinical milestones, evaluate dilution risk, and benchmark executive pay. Our coverage spans every form—from a Tourmaline Bio annual report 10-K simplified to the definitive Tourmaline Bio proxy statement executive compensation—updated the moment EDGAR posts. You will also find nuanced commentary on trial timelines, plus Tourmaline Bio earnings report filing analysis that puts revenue, burn rate, and pipeline progress in context. Start understanding Tourmaline Bio SEC documents with AI and make informed decisions faster.
QVT Financial LP reported beneficial ownership of 2,154,653 shares of Tourmaline Bio, Inc. common stock, representing 8.39% of the class. The filing states these shares are held with sole voting and dispositive power and were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. The document identifies QVT Financial LP as a Delaware entity and provides its address as 888 Seventh Avenue, 43rd Floor, New York, NY 10106. The statement was signed by an authorized signatory on behalf of QVT Financial LP.
Avoro Capital Advisors LLC and Behzad Aghazadeh reported beneficial ownership of 2,555,555 shares of Tourmaline Bio, Inc. common stock, equal to 9.95% of the class. The percentage is calculated using an aggregate of 25,688,479 shares outstanding as disclosed by the company for the quarter ended March 31, 2025.
The filing identifies Avoro as the investment adviser holding the shares on behalf of Avoro Life Sciences Fund LLC and names Dr. Aghazadeh as the portfolio manager and controlling person. The reporting persons state they have sole voting and dispositive power over the reported shares and certify the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.
Tourmaline Bio, Inc. (TRML) reported unaudited results for the quarter ended June 30, 2025 showing continued investment in clinical development of pacibekitug and a solid liquidity position. The company held $256.4 million in cash, cash equivalents and investments and reported a net loss of $46.1 million for the six months ended June 30, 2025, widening from $30.8 million a year earlier due to higher research and development spending.
Research and development expenses rose to $39.9 million for the six-month period, driven by higher clinical trial and toxicology costs as Tourmaline advanced the TRANQUILITY and spiriTED programs. The company disclosed positive Phase 2 TRANQUILITY topline results showing rapid, deep and durable reductions in hs-CRP with quarterly dosing and reported comparable adverse event rates to placebo through the data extract date. Management expects existing funds to support operations into the second half of 2027 and plans further development including a potential Phase 3 cardiovascular outcomes trial and a Phase 2 proof-of-concept study in abdominal aortic aneurysm.
Tourmaline Bio, Inc. furnished a Current Report on Form 8-K stating it issued a press release announcing business highlights and financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The company states this information is being furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless expressly stated.
The 8-K contains no numerical financial data or operational detail itself; readers must consult Exhibit 99.1 for the actual figures and narrative. The registrant's common stock trades under TRML on the Nasdaq Global Select Market and no other material transactions or financial tables are included in this filing.
FAQ
What is the current stock price of Tourmaline Bio (TRML)?
What is the market cap of Tourmaline Bio (TRML)?
